Q BioMed Inc (OTCQB: $QBIO) News: Mannin Research
to Participate at ARVO 2016 Meeting
NEW
YORK - May 2, 2016 (Investorideas.com Newswire) Q BioMed Inc. (OTC: QBIO),
a biotechnology acceleration company announces that its technology partner
Mannin Research Inc. will be attending the Association for Research in Vision
and Ophthalmology (ARVO), which takes place from May 1-5, 2016 in Seattle
Washington. Mannin Research executives will be meeting with its vendors and
research partners. The meeting provides organizations the opportunity to
further explore business development goals and other collaborative
opportunities for the MAN-01 program for treatment of glaucoma.
The
ARVO annual meeting is the largest gathering of eye and vision researchers in
the world. The annual meeting runs from May 1st to 5th at the Washing State
Convention Center in Seattle, Washington, attracting over 11,000 attendees from
more than 75 countries.
Mannin's
CEO, Dr. George N. Nikopoulos stated: "We are very pleased to be attending
the meeting. We are looking forward to engaging in meaningful research
discussions and exploring possible collaboration opportunities with other
innovative groups in attendance."
In
October 2015 Q BioMed Inc entered into an agreement with Mannin Research to
exclusively license, with an option to acquire, the platform technology assets
of Mannin Research, the developer of a new class of vascular therapeutics.
Mannin's primary focus is developing a first-in-class therapeutic eye-drop for
glaucoma in adults and children, using a research platform designed to help
develop new drugs for that indication and cystic kidney disease, among other
diseases. Lead drug candidate MAN-01 is designed to treat abnormal vessels
within the eye-thus treating glaucoma at its root causes.
We
invite our shareholders and interested parties to subscribe to our email list
and stay informed on our website at http://www.qbiomed.com and follow us on the social media feeds we
use.
About Q BioMed Inc.
Q BioMed Inc. ”Q“ is a biomedical acceleration and
development company. We are focused on acquiring companies and biomedical
assets. Q is dedicated to providing these target companies and assets,
strategic resources, developmental support, and expansion capital to ensure
they meet their developmental potential enabling them to provide products to patients
in need.
Forward-Looking
Statements:
This
press release may contain “forward-looking statements” within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such statements include, but are not limited to, any
statements relating to our growth strategy and product development programs and
any other statements that are not historical facts. Forward-looking statements
are based on management’s current expectations and are subject to risks and
uncertainties that could negatively affect our business, operating results,
financial condition and stock price. Factors that could cause actual results to
differ materially from those currently anticipated are: risks related to our
growth strategy; risks relating to the results of research and development
activities; our ability to obtain, perform under and maintain financing and
strategic agreements and relationships; uncertainties relating to preclinical
and clinical testing; our dependence on third-party suppliers; our ability to
attract, integrate, and retain key personnel; the early stage of products under
development; our need for substantial additional funds; government regulation;
patent and intellectual property matters; competition; as well as other risks
described in our SEC filings. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any forward looking
statements contained herein to reflect any change in our expectations or any
changes in events, conditions or circumstances on which any such statement is
based, except as required by law.
Contact:
Denis Corin
CEO
Q BioMed Inc.
1 888 357 2435
Sign up for the
free investor news and stock alerts:
This
news is published on the Investorideas.com Newswire - a global digital news
source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party
sourced news, articles and equity research as well as creates original content,
including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication rights. Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investment involves risk and
possible loss of investment. This site is currently compensated for news
publication and distribution, social media and marketing, content creation and
more. Contact each company directly regarding content and press release
questions. Disclosure is posted for each compensated news release, content
published /created if required but otherwise the news was not compensated for
and was published for the sole interest of our readers and followers. More
disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Disclosure:
QBIO has retained investorideas.com for PR, media, news publication and social
media effective February 5th for three months: two thousand five hundred per
month.
Additional info regarding BC Residents and global Investors:
Effective September 15 2008 - all BC investors should review all OTC and Pink
sheet listed companies for adherence in new disclosure filings and filing
appropriate documents with Sedar. Read for more info:
http://www.bcsc.bc.ca/release.aspx?id=6894. Global
investors must adhere to regulations of each country.
